HLS Therapeutics (TSE:HLS) Stock Price Up 0.8% – Should You Buy?

HLS Therapeutics Inc. (TSE:HLS)’s stock price traded up 0.8% during trading on Monday . The stock traded as high as C$4.89 and last traded at C$4.89. 4,177 shares traded hands during trading, an increase of 14% from the average session volume of 3,677 shares. The stock had previously closed at C$4.85.

HLS Therapeutics Stock Performance

The firm’s fifty day moving average price is C$5.01 and its 200-day moving average price is C$5.17. The company has a market cap of C$152.93 million, a P/E ratio of -10.87 and a beta of 0.49. The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. The business had revenue of C$18.81 million for the quarter. HLS Therapeutics had a negative return on equity of 25.27% and a negative net margin of 38.70%. As a group, research analysts forecast that HLS Therapeutics Inc. will post -0.12 EPS for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.